Prevalence of Hepatitis B and Hepatitis C Virus Infection in Patients with Advanced Renal Failure: A Tertiary Care Centre Study from North Indian Population

Published

2022-12-31

DOI:

https://doi.org/10.47203/IJCH.2022.v34i04.003

Keywords:

Advanced Renal Failure, Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Haemodialysis (HD)

Dimensions Badge

Issue

Section

Original Article

Authors

  • Sumit Rungta King George’s Medical University, Lucknow, Uttar Pradesh
  • Shweta Kumar King George’s Medical University, Lucknow, Uttar Pradesh
  • Sukanya Tripathy King George’s Medical University, Lucknow, Uttar Pradesh https://orcid.org/0000-0001-6745-9447
  • Sant Pandey Chandan Hospital, Lucknow, Uttar Pradesh
  • Kamlendra Verma King George’s Medical University, Lucknow, Uttar Pradesh https://orcid.org/0000-0002-1729-6341
  • Ghulam Akhtar King George’s Medical University, Lucknow, Uttar Pradesh
  • Suchit Swaroop University of Lucknow, Uttar Pradesh https://orcid.org/0000-0001-5142-5875
  • Amar Deep King George’s Medical University, Lucknow, Uttar Pradesh https://orcid.org/0000-0002-8253-5169

Abstract

Abstract: Viral hepatitis (Hepatitis B Virus (HBV) & Hepatitis C Virus (HCV)) related liver disease is a leading cause of morbidity and mortality especially in the patients with advanced renal failure who are treated with dialysis, and this is due to high number of blood transfusion sessions and/or cross contamination from the dialysis circuits. Aims & Objectives: This study aimed to determine the prevalence of HBV and HCV infections in patients with advanced renal failure (ARF). Materials & Methods: A cross-sectional study was done in joint collaboration of Department of Nephrology and Department of Gastroenterology, KGMU, Lucknow, from June 2018 to June 2020 among, CRF patients. Clinical data such as age, gender, duration of dialysis; number of transfusions, Serum sample was collected from each patient. Serological markers for HBV and HCV were determined with ELISA by using commercial diagnostic kits. HCV-RNA and HBV-DNA were determined quantitatively by polymerase chain reaction (PCR) assay. Results: A total 934 patients with advanced renal failure attended the nephrology OPD. Out of 934 patients, 65 (6.96%) patients screened positive for HBV/HCV infection. The results of this study also showed that the prevalence of viral hepatitis infection in the haemodialysis (HD) and without HD patients is 8.25% and 6.3% respectively. Conclusion: It has been found that viral infections, particularly HBV and HCV infections are common in advanced renal failure patients who are on HD.

How to Cite

1.
Rungta S, Kumar S, Tripathy S, Pandey S, Verma K, Akhtar G, Swaroop S, Deep A. Prevalence of Hepatitis B and Hepatitis C Virus Infection in Patients with Advanced Renal Failure: A Tertiary Care Centre Study from North Indian Population. Indian J Community Health [Internet]. 2022 Dec. 31 [cited 2023 Feb. 6];34(4):464-8. Available from: https://iapsmupuk.org/journal/index.php/IJCH/article/view/2483

Downloads

Download data is not yet available.

References

Meyers CM, Seef LB, Stehman-Breen CO, Hoofnagle JH. Hepatitis C and renal disease: an update. Am J Kidney Dis. 2003;42(4):631e657.

Fabrizi F, de Vecchi AF, Como G, Lunghi G, Martin P. De novo HCV infection among dialysis patients: a prospective study by HCV core antigen ELISA assay. Aliment Pharmacol Ther. 2005;21(7):861e869.

Gasiorowicz M, Hurie M, Russell A, Hoxie N, Vergeront J. Epidemiologic trends in infection, mortality, and transplants related to hepatitis C in Wisconsin. WMJ. 2006;105:34e39.

Zacks SL, Fried MW. Hepatitis B and C renal failure. Infect Dis Clin North Am 2001;15:877–899.

Huang CC. Hepatitis in patients with end-stage renal disease. J Gastroenterol Hepatol 1997;12(9-10):236–241.

Agarwal SK, Dash SC, Irshad M, Raju S, Singh R, Pandey RM. Prevalence of chronic renal failure in adults in Delhi, India. Nephrol Dial Transplant. 2005;20(8):1638-42.

KDIGO. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. Suppl. 3, 163 (2013).

Hole B, Hemmelgarn B, Brown E, Brown M, McCulloch MI, et al. Supportive care for end-stage kidney disease: an integral part of kidney services across a range of income settings around the world. Kidney Int Suppl (2011). 2020;10(1):e86-e94.

Deray G, Buti M, Gane E, et al. Hepatitis B Virus Infection and the Kidney: Renal Abnormalities in HBV Patients, Antiviral Drugs Handling, and Specific Follow-Up. Adv Hepatol 2015;2015:596829.

Pol S, Parlati L, Jadoul M. Hepatitis C virus and the kidney. Nat Rev Nephrol. 2019;15(2):73-86.

Arankalle VA, Chadha MS, Jha J, Amrapurkar DN, Banerjee K. Prevalence of anti-HCV antibodies in western India. Indian J Med Res. 1995;101:91e93.

Gosavi MS, Shah SK, Shah SR, Pal RB, Saldanha JA, Banker DD. Prevalence of hepatitis C virus (HCV) infection in Mumbai. Indian J Med Sci. 1997;51(10):378e385.

Chandra M, Khaja MN, Hussain MM, et al. Prevalence of hepatitis B and hepatitis C viral infections in Indian patients with chronic renal failure. Intervirology. 2004;47(6):374e376.

Shantanu Prakash, Amita Jain, S.N. Sankhwar, et al. Prevalence of hepatitis B & C viruses among patients on hemodialysis in Lucknow, Uttar Pradesh, Clinical Epidemiology and Global Health, 2014;2(1):19-23.

Ozer Etik D, Ocal S, Boyacioglu AS. Hepatitis C infection in hemodialysis patients: A review. World J Hepatol. 2015;7(6):885-95.

Prakash S, Jain A, Jain B. Development of novel triplex single?step real?time PCR assay for detection of hepatitis Virus B and C simultaneously. Virology. 2016;492:101?107.

Xu N, Xie Q, Li J, Gao Y, Li X. Improvement in liver stiffness measurement for diagnosis of liver fibrosis in patients with concurrent chronic hepatitis B and nonalcoholic fatty liver disease. J Int Med Res. 2020;48(2):300060520903667.

GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018; 392: 1789–858.

GBD 2017 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018; 392: 1859–922.

Shah AS, Amarapurkar DN. Spectrum of hepatitis B and renal involvement. Liver Int. 2018;38(1):23-32.

Oesterreicher C, Muller C. HBV and HCV genome in peripheral blood mononuclear cells in patients undergoing chronic hemodialysis. Kidney Int. 1995;48:1967e1971.

Devi KS, Singh NB, Mara J, Singh TB, Singh YM. Seroprevalence of Hepatitis B V virus and Hepatitis C Virus among hepatic disorders and injecting drug users in Manipur- A preliminary report. Ind J Medical Microbiol 2004;22(2):136-137.

Anima X, Kumar M, Minz M. Sharma HP, Shahi SK. Prevalence of Hepatitis B and Hepatitis C virus coinfection in chronic liver disease. Indian J Pathol Microbiol 2001; 44(3):253-255.

Berry N, Chakravati A, Sharma VK, Mathur MD. Coinfection with HBV and HIV in HCV infected chronic liver disease. Indian J Med Microbiol 1998;16(1):44.

Agarwal SK, Dash SC. Spectrum of renal diseases in India in adults. J Assoc Physicians India 2000; 48(6): 594–600.

Mittal S, Kher V, Gulati S, Agarwal LK, Arora P. Chronic renal failure in India. Ren Fail 1997; 19(6): 763–770.

Sakuja V, Jha V, Ghosh AK, Ahmed S, Saha TK. Chronic renal failure in India. Nephrol Dial Transplant 1994; 9(7): 871–872.

Mani MK. Chronic renal failure in India. Nephrol Dial Transplant 1993; 8(8): 684–689.

Soni PN, Tait DR, Kenoyer DG. Hepatitis C virus antibodies among risk groups in a South African area endemic for hepatitis B virus. J Med Virol 1993;40(1):65-68.

Goudeau A, Dubois F. Incidence and prevalence of hepatitis B in France. Vaccine 1995;13 Suppl 1:S22-25.

Guh JY, Lai YH, Yang CY, et al. Impact of decreased serum transaminase levels on the evaluation of viral hepatitis in hemodialysis patients. Nephron 1995;69: 459-465.

Muller GY, Zabaleta ME, Arminio A, et al. Risk factors for dialysis associated hepatitis C in Venezuela. Kidney Int 1992;41:1055-1058.

Jadoul M, Bieber BA, Martin P, et al. Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients. Kidney Int 2019;95(4):939-947.